Lazertinib tablets 80 mg/tablet, 60 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Venous thromboembolic events (VTE): Prophylactic anticoagulant therapy is recommended for the first four months of treatment. Monitor for signs and symptoms of VTE and treat as appropriate. Suspend LuciLazer and amivantamab depending on severity. After starting anticoagulant therapy, the same dose of LuciLazer and amivantamab should be resumed as recommended by the healthcare provider. Even if treated with therapeutic anticoagulation, if the VTE recurs, Amivantamab should also be permanently discontinued and LuciLazer continued.
• Interstitial lung disease (ILD)/pneumonia: Monitor for new or worsening symptoms of ILD/pneumonia. Patients with suspected ILD/pneumonia should discontinue LuciLazer and amivantamab and permanently discontinue if ILD/pneumonia is diagnosed.
• Adverse skin effects: May cause severe rashes, including acne-like dermatitis. Patients are advised to use a non-alcoholic moisturizer and are encouraged to reduce sun exposure during and within 2 months of treatment to reduce the risk of skin reactions. Suspend, reduce the dose or permanently discontinue LuciLazer and amivantamab, depending on the severity.
• Ocular Adverse Reactions: Patients with signs and symptoms of new or worsening ocular adverse reactions, including keratitis, should be referred to an ophthalmologist immediately for evaluation. Depending on the severity, interrupt, reduce the dose or permanently discontinue amivantamab and continue to use LuciLazer.
• Embryo-fetal toxicity: May cause damage to the fetus. Patients of childbearing potential are advised to be aware of the potential risks to the fetus and to take effective contraceptive measures.

Medication risks

Adverse Reactions
LuciLazer in combination with Amivantamab
• The most common adverse reactions (≥ 20%) include rash, nail toxicity, infusion-related reactions (amivantumab), musculoskeletal pain, edema, stomatitis, venous thromboembolism (VTE), paresthesia, fatigue, diarrhea, constipation, COVID-19, bleeding, dry skin, decreased appetite, itching, nausea, and eye toxicity.
• The most common grade 3 or 4 laboratory abnormalities (≥ 2%) include decreased albumin, decreased sodium, increased alanine aminotransferase (ALT), decreased potassium, decreased hemoglobin, increased aspartate aminotransferase (AST), increased glutamyl transpeptidase (GGT), and increased magnesium.